These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15164802)

  • 1. What is next for pharmacoeconomics and outcomes research in Asia?
    Doherty J; Kamae I; Lee KK; Li H; Li SC; Liu GG; Tarn YH; Yang BM
    Value Health; 2004; 7(2):118-32. PubMed ID: 15164802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacoeconomics in the new millennium. A pharmaceutical industry perspective.
    Thwaites R; Townsend RJ
    Pharmacoeconomics; 1998 Feb; 13(2):175-80. PubMed ID: 10178645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growing application of pharmacoeconomics and outcomes research in health-care decision-making in the Asia-Pacific region.
    Yang BM; Lee K
    Value Health; 2009; 12 Suppl 3():S1-2. PubMed ID: 20586968
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacoeconomics and immunotherapy.
    Berto P
    Eur Ann Allergy Clin Immunol; 2007; 39 Spec No():12-6. PubMed ID: 18924461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging role of pharmacoeconomics in the research and development decision-making process.
    DiMasi JA; Caglarcan E; Wood-Armany M
    Pharmacoeconomics; 2001; 19(7):753-66. PubMed ID: 11548911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-care systems and pharmacoeconomic research in Asia-Pacific region.
    Tarn YH; Hu S; Kamae I; Yang BM; Li SC; Tangcharoensathien V; Teerawattananon Y; Limwattananon S; Hameed A; Aljunid SM; Bapna JS
    Value Health; 2008 Mar; 11 Suppl 1():S137-55. PubMed ID: 18387058
    [No Abstract]   [Full Text] [Related]  

  • 7. Bridging the gap in pharmacoeconomics and outcomes research between researchers, policymakers, and practitioners in the Asia-Pacific region.
    Kulsomboon V; Yang BM; Hu S
    Value Health; 2012; 15(1 Suppl):S1-2. PubMed ID: 22265053
    [No Abstract]   [Full Text] [Related]  

  • 8. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Part 5. Public health and air pollution in Asia (PAPA): a combined analysis of four studies of air pollution and mortality.
    Wong CM; Vichit-Vadakan N; Vajanapoom N; Ostro B; Thach TQ; Chau PY; Chan EK; Chung RY; Ou CQ; Yang L; Peiris JS; Thomas GN; Lam TH; Wong TW; Hedley AJ; Kan H; Chen B; Zhao N; London SJ; Song G; Chen G; Zhang Y; Jiang L; Qian Z; He Q; Lin HM; Kong L; Zhou D; Liang S; Zhu Z; Liao D; Liu W; Bentley CM; Dan J; Wang B; Yang N; Xu S; Gong J; Wei H; Sun H; Qin Z;
    Res Rep Health Eff Inst; 2010 Nov; (154):377-418. PubMed ID: 21446215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of Information in Asia: Concepts, Current Use, and Future Directions.
    Dilokthornsakul P; McQueen RB; Chaiyakunapruk N; Spackman E; Watanabe JH; Campbell JD
    Value Health Reg Issues; 2016 May; 9():99-104. PubMed ID: 27881269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacoeconomic picture in Saudi Arabia.
    Alkhenizan A
    Expert Rev Pharmacoecon Outcomes Res; 2014 Aug; 14(4):483-90. PubMed ID: 24953076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Barriers and Facilitators of Pharmacoeconomic Studies: A Review of Evidence from the Middle Eastern Countries.
    Alzarea AI; Khan YH; Alanazi AS; Butt MH; Almalki ZS; AlAhmari AK; Alsahali S; Mallhi TH
    Int J Environ Res Public Health; 2022 Jun; 19(13):. PubMed ID: 35805521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Third Asian and Pacific Conference perspectives on family planning, population, and development.
    United Nations. Economic and Social Commission for Asia and the Pacific ESCAP. Population Division
    Asian Pac Popul Programme News; 1984; 13(2):25-30. PubMed ID: 12313216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoeconomics: an emerging discipline.
    Letizia C
    Qual Assur; 1995 Mar; 4(1):68-74. PubMed ID: 8520866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Penny and pound wise: pharmacoeconomics from a governmental perspective.
    van Oostenbruggen MF; Jansen RB; Mur K; Kooijman H
    Pharmacoeconomics; 2005; 23(3):219-26. PubMed ID: 15836004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Health outcomes analysis and its applications].
    Carrera-Hueso FJ
    Rev Med Univ Navarra; 1997; 41(4):237-44. PubMed ID: 10420964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. India (country/area statements).
    Asian Pac Popul Programme News; 1985 Sep; 14(3):9-10. PubMed ID: 12267461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population planning: a well co-ordinated approach required.
    Asian Pac Popul Programme News; 1984; 13(1):17-9. PubMed ID: 12313052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.